CD276 recombinant proteins refer to engineered versions of the CD276 protein, also known as B7-H3 (B7-H3), which is a member of the B7 family of immune checkpoint molecules. CD276 is involved in regulating immune responses and is expressed in various tissues, including tumors, where it can modulate immune cell activity. Recombinant CD276 proteins are important tools for studying immune regulation, cancer immunotherapy, and the development of new therapeutic strategies.
Structure and Function
- CD276 (B7-H3) is a glycosylated membrane protein that belongs to the B7 family of immune checkpoint molecules. It contains an extracellular domain, a single transmembrane domain, and a short intracellular domain.
- The extracellular domain of CD276 interacts with receptors on immune cells, influencing immune responses. It can either co-stimulate or inhibit T cell activation, depending on the cellular context.
- Recombinant CD276 proteins typically include the extracellular domain or full-length protein for functional studies and therapeutic applications.
Production
- CD276 recombinant proteins are produced in various expression systems such as E. coli, yeast, insect cells, or mammalian cells, depending on the need for proper post-translational modifications like glycosylation.
- The gene encoding CD276 is cloned into an expression vector, and the protein is expressed and purified using techniques like affinity chromatography, often with tags such as His-tag or GST-tag to facilitate isolation.
Applications
- Cancer Research: Recombinant CD276 proteins are used to investigate the role of CD276 in tumor immune evasion, as it is often overexpressed in various cancers and can inhibit anti-tumor immune responses.
- Immunotherapy Development: CD276 is a potential target for cancer immunotherapy. Recombinant proteins are used to develop and test monoclonal antibodies or other therapeutic agents designed to block CD276 interactions and enhance immune responses against tumors.
- Diagnostics: Recombinant CD276 proteins can be used in diagnostic assays to measure CD276 expression levels in tissues or fluids, helping to assess the role of CD276 in disease progression and response to therapy.
- Basic Research: These proteins are crucial for understanding CD276’s function in immune regulation, its interactions with immune cell receptors, and its impact on immune system dynamics.
Validation and Quality Control
- Validation of recombinant CD276 proteins involves confirming their identity and purity through methods like SDS-PAGE, Western blotting, and mass spectrometry.
- Functional assays, such as receptor-binding studies or cell-based assays, ensure that the recombinant proteins are biologically active and capable of interacting with their intended targets.
|
|
|
|
|
|
|
|
|
|
|